Acorda Therapeutics Elects John Kelley Chair, Board of Directors
November 27 2019 - 7:00AM
Business Wire
Acorda Therapeutics, Inc. (NASDAQ: ACOR) today announced that
its Board of Directors has elected John Kelley to serve as
non-executive board Chair, effective November 25, 2019. Mr. Kelley
has been a board member at Acorda since 2008.
“I am delighted that John will be chairing Acorda’s board,” said
Ron Cohen, M.D., Acorda's President and CEO. “John has extensive
senior leadership and commercial experience in the
biopharmaceutical industry, and we expect that he will enhance the
board’s governance in his new role as Chair.”
“I’m honored to serve as Chair of the Acorda board,” said Mr.
Kelley. “During my time as a director, Acorda has brought two
important therapies to market – AMPYRA, which has become a standard
of care to improve walking in people with multiple sclerosis, and
most recently, INBRIJA for on-demand treatment of OFF periods by
people with Parkinson’s disease. I believe that INBRIJA, likewise,
will become a standard of care for those living with Parkinson’s,
and am looking forward to continuing to work with the Board, Ron
and Acorda’s leadership team to build value on behalf of all of the
company’s stakeholders.”
From 2013 until 2017, Mr. Kelley was the Chief Executive Officer
of Tenax Therapeutics, Inc. a biotechnology company developing
products for the critical care market; he was also a member of its
board of directors. Previously he was the President, Chief
Executive Officer and a director of Phyxius Pharma. From 2004 to
2009, Mr. Kelley was the President and Chief Operating Officer of
The Medicines Company, a pharmaceutical company providing acute
care hospital products worldwide. He was a member of their board of
directors from 2005 to 2009.
He also held a number of senior level positions at Aventis. Mr.
Kelley received a B.A. from Wilkes University and an M.B.A. from
Rockhurst University.
About Acorda Therapeutics
Acorda Therapeutics develops therapies to restore function and
improve the lives of people with neurological disorders. INBRIJA™
(levodopa inhalation powder) is approved for intermittent treatment
of OFF episodes in adults with Parkinson’s disease treated with
carbidopa/levodopa. INBRIJA is not to be used by patients who take
or have taken a nonselective monoamine oxidase inhibitor such as
phenelzine or tranylcypromine within the last two weeks. INBRIJA
utilizes Acorda’s innovative ARCUS® pulmonary delivery system, a
technology platform designed to deliver medication through
inhalation. Acorda also markets the branded AMPYRA® (dalfampridine)
Extended Release Tablets, 10 mg.
Forward-Looking Statement
This press release includes forward-looking statements. All
statements, other than statements of historical facts, regarding
management's expectations, beliefs, goals, plans or prospects
should be considered forward-looking. These statements are subject
to risks and uncertainties that could cause actual results to
differ materially, including: we may not be able to successfully
market Inbrija or any other products under development; risks
associated with complex, regulated manufacturing processes for
pharmaceuticals, which could affect whether we have sufficient
commercial supply of Inbrija to meet market demand; third party
payers (including governmental agencies) may not reimburse for the
use of Inbrija or our other products at acceptable rates or at all
and may impose restrictive prior authorization requirements that
limit or block prescriptions; competition for Inbrija, Ampyra and
other products we may develop and market in the future, including
increasing competition and accompanying loss of revenues in the
U.S. from generic versions of Ampyra (dalfampridine) following our
loss of patent exclusivity; the ability to realize the benefits
anticipated from acquisitions, among other reasons because acquired
development programs are generally subject to all the risks
inherent in the drug development process and our knowledge of the
risks specifically relevant to acquired programs generally improves
over time; we may need to raise additional funds to finance our
operations and may not be able to do so on acceptable terms; the
risk of unfavorable results from future studies of Inbrija
(levodopa inhalation powder) or from our other research and
development programs, or any other acquired or in-licensed programs
; the occurrence of adverse safety events with our products; the
outcome (by judgment or settlement) and costs of legal,
administrative or regulatory proceedings, investigations or
inspections, including, without limitation, collective,
representative or class action litigation; failure to protect our
intellectual property, to defend against the intellectual property
claims of others or to obtain third party intellectual property
licenses needed for the commercialization of our products; and
failure to comply with regulatory requirements could result in
adverse action by regulatory agencies.
These and other risks are described in greater detail in our
filings with the Securities and Exchange Commission. We may not
actually achieve the goals or plans described in our
forward-looking statements, and investors should not place undue
reliance on these statements. Forward-looking statements made in
this press release are made only as of the date hereof, and we
disclaim any intent or obligation to update any forward-looking
statements as a result of developments occurring after the date of
this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191127005132/en/
Felicia Vonella (914) 326-5146 fvonella@acorda.com
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Sep 2023 to Sep 2024